$496 Mln
$-137 Mln
--
As on 29-Sep-2023 16:00 EDT
$-0.04
•
-0.22%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
AnaptysBio (ANAB)
| -42.05 | -11.83 | -13.70 | -31.29 | 8.22 | -29.03 | -- |
|
S&P BSE Sensex
| 8.20 | 1.28 | 2.99 | 16.31 | 20.12 | 12.69 | 12.81 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|
|
AnaptysBio (ANAB)
| -10.82 | 61.63 | 32.31 | -74.53 | -36.51 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of AnaptysBio Inc. (ANAB) stood at $ 588 Mln as on 31-Mar-23
The share price of AnaptysBio Inc. (ANAB) is $17.960000 (NASDAQ) as of 29-Sep-2023 16:00 EDT. AnaptysBio Inc. (ANAB) has given a return of 8.22% in the last 3 years.
AnaptysBio Inc. (ANAB) has a market capitalisation of $ 496 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of AnaptysBio Inc. (ANAB) is 3.00 times as on 02-Jun-2023, a 0.18% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of AnaptysBio Inc. (ANAB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the AnaptysBio Inc. (ANAB) and enter the required number of quantities and click on buy to purchase the shares of AnaptysBio Inc. (ANAB).
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
The CEO & director of Mr. Daniel R. Faga. is AnaptysBio Inc. (ANAB), and CFO & Sr. VP is Mr. Eric J. Loumeau.
The promoters of AnaptysBio Inc. (ANAB) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
313
|
|
|
286
|
|
|
34
|
|
|
10
|
| AnaptysBio Inc. (ANAB) | Ratios |
|---|---|
|
Return on equity(%)
|
-63.81
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of AnaptysBio Inc. (ANAB) was $-137 Mln.
$495.84 Mln
$10.69 Mln
$-136.72 Mln
$431.15 Mln
$19.06 Mln
High
$16.52 - 32.44
26,487,200
NASDAQ: ANAB
San Diego, CA
https://www.anaptysbio.com
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of... generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
